Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
R&D Roundup: Pharma gets in on the biotech boomSome good news for the UK industry in turbulent times is always welcome, and several announcement this month Share XR&D Roundup: Pharma gets in on the biotech boomhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/
A lifeline for rare disease patientsFor more than 25 years Alexion has been blazing a trail in rare diseases, bringing a series of Share XA lifeline for rare disease patientshttps://deep-dive.pharmaphorum.com/magazine/pharma-research-rare-diseases/alexion-sean-richardson-charles-de-wet/
Alexion signs R&D deals with two Nordic biotechsAlexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs. Share XAlexion signs R&D deals with two Nordic biotechshttps://pharmaphorum.com/news/alexion-signs-rd-deals-with-two-nordic-biotechs/
Alexion aims for fourth rare disease use for blockbuster SolirisThe FDA has granted a fast review for Alexion Pharmaceuticals’ filing for its Soliris, as a treatment for Share XAlexion aims for fourth rare disease use for blockbuster Solirishttps://pharmaphorum.com/news/alexion-aims-for-fourth-rare-disease-use-for-blockbuster-soliris/
Alexion joins with Dicerna to develop RNAi therapies for complement diseasesAlexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused Share XAlexion joins with Dicerna to develop RNAi therapies for complement diseaseshttps://pharmaphorum.com/news/alexion-joins-with-dicerna-to-develop-rnai-therapies-for-complement-diseases/
Alexion buys rare diseases biotech Syntimmune for up to $1.2bnAlexion is to buy rare diseases biotech Syntimmune and its experimental drug for a rare kind of anaemia, Share XAlexion buys rare diseases biotech Syntimmune for up to $1.2bnhttps://pharmaphorum.com/news/alexion-buys-rare-diseases-biotech-syntimmune-for-up-to-1-2bn/
Alexion prepares filings for new rare disease use for SolirisAlexion is preparing filings in major markets for its rare disease drug Soliris in a new indication after Share XAlexion prepares filings for new rare disease use for Solirishttps://pharmaphorum.com/news/alexion-prepares-filings-for-new-rare-disease-use-for-soliris/
Alexion hastens review of successor to rare disease blockbuster SolirisAlexion’s rare disease drug Soliris is generating blockbuster-level sales – but the US biotech is rushing through development Share XAlexion hastens review of successor to rare disease blockbuster Solirishttps://pharmaphorum.com/news/alexion-hastens-review-of-successor-to-rare-disease-blockbuster-soliris/
